Table 2

Adverse events by treatment visita

Adverse event groupIntranasal (N = 77) Intramuscular (N = 76)
GI
 Abdominal discomfort1 (1)1 (1)
 Nausea17 (22)21 (28)
 Vomiting13 (17)9 (12)
 Total (≥1 GI events)b28 (36)29 (38)
Head discomfort
 Ear pain2 (3)1 (1)
 Eye pain1 (1)0
 Facial pain2 (3)0
 Headache18 (23)7 (9)
 Neck pain1 (1)0
 Total (≥1 head pain events)b19 (25)7 (9)
Nasal
 Nasal congestion6 (8)1 (1)
 Nasal discomfort8 (10)0
 Nasal edema1 (1)0
 Rhinorrhoea2 (3)1 (1)
 Total (≥1 nasal events)b14 (18)1 (1)
Weakness/fatigue
 Fatigue6 (8)5 (7)
 Lethargy01 (1)
 Muscular weakness2 (3)0
 Total (≥1 weakness/fatigue events)b8 (10)6 (8)
Ocular
 Eye pruritus2 (3)1 (1)
 Lacrimation increased7 (9)1 (1)
 Ocular hyperemia1 (1)0
 Total (≥1 ocular events)b7 (9)1 (1)
Cognitive
 Confusional state1 (1)0
 Disturbance in attention1 (1)0
 Somnolence2 (3)0
 Total (≥1 cognitive events)b2 (3)0
Autonomic
 Hot flush01 (1)
 Hyperhidrosis1 (1)1 (1)
 Total (≥1 autonomic events)b1 (1)2 (3)
Throat
 Cough1 (1)0
 Upper-airway cough syndrome1 (1)0
 Total (≥1 throat events)b2 (3)0
Skin: pruritus2 (3)1 (1)
Hyperglycemia1 (1)0
Psychological: anxiety1 (1)0
  • Data are n (%). No serious adverse events were reported. GI, gastrointestinal.

  • aForty-four (57%) of 77 participants receiving intranasal glucagon experienced at least 1 adverse event; 35 (46%) of 76 participants receiving intramuscular glucagon experienced at least 1 adverse event.

  • bTotal number (%) of participants with at least 1 occurrence of the adverse event group.